The Louisiana House Criminal Justice Committee convened on May 28, 2025, to discuss a controversial bill concerning the disclosure of sexually transmitted infections (STIs), particularly focusing on HPV and HSV. The meeting highlighted significant concerns from medical professionals and advocates regarding the implications of the proposed legislation.

During the session, a medical expert expressed deep reservations about the bill, arguing that it fails to accurately reflect the realities of HPV and HSV infections. The expert noted that a substantial percentage of adults will contract HPV or HSV at some point in their lives, yet many remain unaware of their status due to inadequate screening practices. The discussion emphasized that current STI testing does not routinely include these infections, leading to a lack of awareness among individuals who may unknowingly transmit them.

The bill aims to address the issue of non-disclosure of STI status to partners, but critics argue that it could lead to unjust criminalization of individuals living with these infections. Dakeetra Griffin, a public health advocate and survivor of sexual violence, shared his personal experience with HIV and herpes, urging lawmakers to reconsider the bill's approach. He argued that the legislation could perpetuate stigma and harm rather than protect public health, emphasizing the need for care and support rather than criminal penalties.

The committee members engaged in a robust dialogue about the definitions of intent and consent within the bill, with some representatives advocating for clearer language to prevent potential misuse of the law. The discussion revealed a shared concern about the balance between protecting public health and ensuring that individuals are not unfairly punished for their health conditions.

As the meeting concluded, several stakeholders expressed their opposition to the bill in its current form, calling for further amendments to ensure it does not criminalize individuals living with chronic health conditions. The committee's next steps remain uncertain, but the discussions highlighted the complexities surrounding STI disclosure and the need for a thoughtful approach to public health legislation.